Screening for sexually transmitted infections during hepatitis c treatment to predict reinfection among people with HIV

Hill, Lucas A; Martin, Natasha K; Torriani, Francesca J; Jain, Sonia; Qin, Huifang; Mathews, Wm Christopher; Cachay, Edward R

Screening for sexually transmitted infections during hepatitis c treatment to predict reinfection among people with HIV

Files

ofaa643.pdf (209.99 KB)

Authors

Hill, Lucas A

Martin, Natasha K

Torriani, Francesca J

Jain, Sonia

Qin, Huifang

Mathews, Wm Christopher

Cachay, Edward R

Issue Date

2020-12-30

Type

Article

Language

en_US

Keywords

Sexually Transmitted Infections , Direct-Acting Antivirals , Hepatitis C , HIV , Reinfection

Abstract

Background: Little is known about the risk of hepatitis C virus (HCV) reinfection among people with HIV (PWH) in the direct-acting antiviral (DAA) era. We evaluate HCV reinfection rates in the DAA era and characterize presustained virologic response (SVR) behavioral risk factors associated with reinfection among PWH at the University of California, San Diego (UCSD). Methods: Observational longitudinal cohort of PWH treated with DAAs between 2014 and July 2019 who achieved SVR and had at least 1 subsequent HCV viral load measurement. HCV reinfection was defined as new HCV viremia after SVR. We examined whether screening for sexually transmitted infections (STIs) and substance use during the pre-SVR period could identify patients at greater risk for reinfection using exact Poisson regression to compare reinfection incidence rates between those with and without pre-SVR STIs and positive urine drug screens. Results: Eight out of 200 PWH were reinfected with HCV a median ~26 weeks after SVR over 328.1 person-years of follow-up (PYFU), for an incidence rate of 2.44/100 PYFU. The observed HCV reinfection rate was highest among men who have sex with men who inject drugs (MSM IDU; 4.63/100 PFYU) and those aged 30–39 years (6.80/100 PYFU). Having a positive gonorrhea/chlamydia test during the pre-SVR period was a predictor of HCV reinfection. Conclusions: The HCV reinfection rate in the DAA era is similar to the rate observed in the interferon era in San Diego in PWH. STI screening during HCV treatment may help determine those at higher risk for HCV reinfection.

Citation

Hill, L. A., Martin, N. K., Torriani, F. J., Jain, S., Qin, H., Mathews, W. C., & Cachay, E. R. (2020). Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV. Open forum infectious diseases, 8(2), ofaa643. https://doi.org/10.1093/ofid/ofaa643

Publisher

Open Forum Infectious Diseases